Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors
暂无分享,去创建一个
H. Koga | Toru Nakamura | Yihai Cao | T. Yoshizumi | T. Torimura | S. Shimose | H. Yano | M. Nakayama | H. Iwamoto | R. Kuromatsu | T. Niizeki | T. Shirono | M. Nakano | Y. Noda | N. Kamachi | M. Sakai | Hiroyuki Suzuki | Toshimitsu Tanaka | Atsutaka Masuda | Takahiko Sakaue | Yasuko Imamura | Takahiro Seki | K. Morita
[1] M. Moriguchi,et al. Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma , 2021, Liver Cancer.
[2] H. Koga,et al. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice , 2021, Cancers.
[3] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[4] H. Koga,et al. Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma. , 2021, ESMO open.
[5] P. Seidel,et al. HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice , 2020, Nature Communications.
[6] H. Koga,et al. Primary Treatment with Molecular‐Targeted Agents for Hepatocellular Carcinoma: A Propensity Score‐matching Analysis , 2020, Hepatology communications.
[7] T. Kawaguchi,et al. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis , 2020, Oncology letters.
[8] E. D. De Toni,et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects , 2020, Signal Transduction and Targeted Therapy.
[9] Yulei N. Wang,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.
[10] P. Radhakrishnan,et al. Role of Tumor and Stroma-Derived IGF/IGFBPs in Pancreatic Cancer , 2020, Cancers.
[11] H. Koga,et al. Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events , 2020, Cancers.
[12] H. Fukuda,et al. Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma , 2020, Cancers.
[13] E. Li,et al. Serum IGFBP-1 as a potential biomarker for diagnosis of early-stage upper gastrointestinal tumour , 2020, EBioMedicine.
[14] Thomas A. Slater,et al. Insulin-like growth factor binding proteins and angiogenesis: from cancer to cardiovascular disease. , 2019, Cytokine & growth factor reviews.
[15] Yihai Cao,et al. Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance. , 2018, Cell metabolism.
[16] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[17] R. Paschke,et al. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. , 2017, European journal of cancer.
[18] AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.
[19] Yihai Cao,et al. Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism , 2016, Nature Communications.
[20] M. Kudo,et al. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON , 2016, Journal of Gastroenterology.
[21] J. Llovet,et al. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma , 2015, Gut.
[22] M. Negishi,et al. Pregnane X Receptor Represses HNF4α Gene to Induce Insulin-Like Growth Factor–Binding Protein IGFBP1 that Alters Morphology of and Migrates HepG2 Cells , 2015, Molecular Pharmacology.
[23] Chih-Hung Hsu,et al. Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? , 2015, World journal of gastroenterology.
[24] Qiang Liu,et al. Effect of hypoxia on hypoxia inducible factor-1α, insulin-like growth factor I and vascular endothelial growth factor expression in hepatocellular carcinoma HepG2 cells , 2015, Oncology letters.
[25] Y. Li,et al. Insulin-like growth factor binding protein-1 inhibits cancer cell invasion and is associated with poor prognosis in hepatocellular carcinoma. , 2014, International journal of clinical and experimental pathology.
[26] Björn Usadel,et al. Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..
[27] C. Hanemann,et al. Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival , 2012, Oncogene.
[28] Douglas Hanahan,et al. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .
[29] J. Bruix,et al. Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.
[30] G. Melillo,et al. Role of the VEGF/VEGFR axis in cancer biology and therapy. , 2012, Advances in cancer research.
[31] Colin N. Dewey,et al. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.
[32] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[33] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[34] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[35] D. George,et al. Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. , 2007, Genes & development.
[36] A. Joe,et al. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.
[37] Oriol Casanovas,et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.
[38] J. Kim,et al. Uterine receptivity and implantation: The regulation and action of insulin-like growth factor binding protein-1 (IGFBP-1), HOXA10 and forkhead transcription factor-1 (FOXO-1) in the baboon endometrium , 2004, Reproductive biology and endocrinology : RB&E.
[39] A I Saeed,et al. TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.
[40] Brad T. Sherman,et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.
[41] D. Yee,et al. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. , 2002, Cancer research.
[42] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[43] S. Weinzimer,et al. Cellular Actions of Insulin-Like Growth Factor Binding Proteins , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[44] M. Kojiro,et al. A NEW HUMAN PLEOMORPHIC HEPATOCELLULAR CARCINOMA CELL LINE, KYN‐2 , 1988, Acta pathologica japonica.